- Home
- AUPH vs MESO Comparison
AUPH vs MESO Comparison
Compare AUPH & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- MESO
- Stock Information
- Founded
- AUPH 1993
- MESO 2004
- Country
- AUPH Canada
- MESO Australia
- Employees
- AUPH N/A
- MESO N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AUPH Health Care
- MESO Health Care
- Exchange
- AUPH Nasdaq
- MESO Nasdaq
- Market Cap
- AUPH 1.0B
- MESO 1.1B
- IPO Year
- AUPH 1999
- MESO N/A
- Fundamental
- Price
- AUPH $8.12
- MESO $10.04
- Analyst Decision
- AUPH Strong Buy
- MESO Strong Buy
- Analyst Count
- AUPH 3
- MESO 4
- Target Price
- AUPH $10.33
- MESO $11.50
- AVG Volume (30 Days)
- AUPH 1.3M
- MESO 204.9K
- Earning Date
- AUPH 11-07-2024
- MESO 08-28-2024
- Dividend Yield
- AUPH N/A
- MESO N/A
- EPS Growth
- AUPH N/A
- MESO N/A
- EPS
- AUPH N/A
- MESO N/A
- Revenue
- AUPH $220,361,000.00
- MESO $5,902,000.00
- Revenue This Year
- AUPH $36.52
- MESO $66.05
- Revenue Next Year
- AUPH $19.02
- MESO $348.27
- P/E Ratio
- AUPH N/A
- MESO N/A
- Revenue Growth
- AUPH 38.72
- MESO N/A
- 52 Week Low
- AUPH $4.71
- MESO $1.61
- 52 Week High
- AUPH $10.05
- MESO $12.18
- Technical
- Relative Strength Index (RSI)
- AUPH 62.64
- MESO 55.85
- Support Level
- AUPH $8.06
- MESO $8.52
- Resistance Level
- AUPH $8.70
- MESO $12.18
- Average True Range (ATR)
- AUPH 0.34
- MESO 0.63
- MACD
- AUPH 0.07
- MESO 0.17
- Stochastic Oscillator
- AUPH 63.74
- MESO 57.96
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.